2C-B is a hallucinogenic phenethylamine derived from mescaline. First made by the grand wizard of psychedelic biochemistry Sasha Shulgin in 1974, 2C-B became his favourite of the "magical-half dozen" of substituted phenethylamines. Published in his seminal book PIHKAL, 2C-B promptly reached the wider world of recreational users. However, despite being the most popular 2C-X compound… Continue reading How does 2C-B compare to psilocybin and placebo regarding subjective effects, mood and cognition?
Our very own Prof. Kim Kuypers talks about the psychedelic research carried out at our department for DOCS! Click on the link to listen to the Trip Generation episode (in Dutch).
Does context matter for brain fingerprints? Like the ridges and grooves of our fingerprints, brain functional connectivity architecture can help define us. Here we examined how might brain fingerprints alter as a result of the collective use of ayahuasca. Our results highlight the presence of a shared functional space under ritualistic ayahuasca use, similarly to… Continue reading Ritualistic use of ayahuasca enhances a shared functional connectome identity with others.
On September 28 uniMIND Central Session will host Mauro Cavarra for an open discussion on our recently published paper reviewing the different models of psychedelic-assisted psychotherapy used in clinical trials. The session will start at 7pm (CEST) and anyone is welcome to join via the MIND Community Platform.
Do psychedelics work for chronic pain? We asked the patients themselves! In our recent article we present the results of a survey study addressed to chronic pain sufferers who are using psychedelics (both in full doses and in microdoses) to seek relief. Our results support the hypothesis that both dosing regimens hold promise for chronic… Continue reading Analgesic potential of psychedelics in chronic pain sufferers: a population survey